摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

N-(4-morpholinophenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine | 878426-13-2

中文名称
——
中文别名
——
英文名称
N-(4-morpholinophenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
英文别名
DSM158;5-methyl-N-(4-morpholinophenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine;5-methyl-N-(4-morpholin-4-ylphenyl)-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine
N-(4-morpholinophenyl)-5-methyl-[1,2,4]triazolo[1,5-a]pyrimidin-7-amine化学式
CAS
878426-13-2
化学式
C16H18N6O
mdl
MFCD07396641
分子量
310.359
InChiKey
HCJBGFOJFCXBIG-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    23
  • 可旋转键数:
    3
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.31
  • 拓扑面积:
    67.6
  • 氢给体数:
    1
  • 氢受体数:
    6

反应信息

  • 作为产物:
    参考文献:
    名称:
    Lead Optimization of Aryl and Aralkyl Amine-Based Triazolopyrimidine Inhibitors of Plasmodium falciparum Dihydroorotate Dehydrogenase with Antimalarial Activity in Mice
    摘要:
    Malaria is one of the leading causes of severe infectious disease worldwide; yet, our ability to maintain effective therapy to combat the illness is continually challenged by the emergence of drug resistance. We previously reported identification of a new class of triazolopyrimidine-based Plasmodium falciparum dihydroorotate dehydrogenase (PfDHODH) inhibitors with antimalarial activity, leading to the discovery of a new lead series and novel target for drug development. Active compounds from the series contained a triazolopyrimidine ring attached to an aromatic group through a bridging nitrogen atom. Herein, we describe systematic efforts to optimize the aromatic functionality with the goal of improving potency and in vivo properties of compounds from the series. These studies led to the identification of two new substituted aniline moieties (4-SF(5)-Ph and 3,5-Di-F-4-CF(3)-Ph), which, when coupled to the triazolopyrimidine ring, showed good plasma exposure and better efficacy in the Plasmodium berghei mouse model of the disease than previously reported compounds from the series.
    DOI:
    10.1021/jm200265b
点击查看最新优质反应信息

文献信息

  • [EN] DIHYDROOROTATE DEHYDROGENASE INHIBITORS WITH SELECTIVE ANTI-MALARIAL ACTIVITY<br/>[FR] INHIBITEURS DE DIHYDROOROTATE DÉSHYDROGÉNASE PRÉSENTANT UNE ACTIVITÉ ANTIPALUDÉENNE SÉLECTIVE
    申请人:UNIV TEXAS
    公开号:WO2009082691A1
    公开(公告)日:2009-07-02
    Compounds according to Formula (I), Formula (II), Formula (III), Formula (V), Formula (VI), or to Formula (VII), and pharmaceutical compositions of compounds that conform to Formula (IV) or (Formula VIII): where R1 through R33 are prescribed, selectively inhibit P. falciparum dihydroorotate dehydrogenase. Accordingly, a method for preventing and treating malaria attaches to such compounds, as well as to pharmaceutically acceptable salts, solvates, stereoisomers, tautomers, and prodrugs thereof.
    根据公式(I),公式(II),公式(III),公式(V),公式(VI)或公式(VII)合成的化合物,以及符合公式(IV)或(公式VIII)的化合物的药物组合物,其中R1至R33被规定,选择性地抑制疟原虫脱氢鸟嘌呤酸脱氢酶。因此,一种预防和治疗疟疾的方法涉及与这些化合物以及其药用可接受的盐,溶剂化物,立体异构体,互变异构体和前药结合。
  • DIHYDROOROTATE DEHYDROGENASE INHIBITORS WITH SELECTIVE ANTI-MALARIAL ACTIVITY
    申请人:PHILLIPS Margaret
    公开号:US20090209557A1
    公开(公告)日:2009-08-20
    Compounds according to Formula I, Formula II, Formula III, Formula V, Formula VI, or to Formula VII, and pharmaceutical compositions of compounds that conform to Formula IV or Formula VIII: where R 1 through R 33 are prescribed, selectively inhibit P. falciparum dihydroorotate dehydrogenase. Accordingly, a method for preventing and treating malaria attaches to such compounds, as well as to pharmaceutically acceptable salts, solvates, stereoisomers, tautomers, and prodrugs thereof.
    按照公式I,公式II,公式III,公式V,公式VI或公式VII制备的化合物和符合公式IV或公式VIII的化合物的制药组合物:其中R1到R33被规定,可以选择性地抑制P. falciparum脱氢鞘酸脱氢酶。因此,一种预防和治疗疟疾的方法涉及到这些化合物,以及其药学上可接受的盐,溶剂化合物,立体异构体,互变异构体和前药。
  • US9216983B2
    申请人:——
    公开号:US9216983B2
    公开(公告)日:2015-12-22
查看更多